Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.41 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061217 | 0.81 | MAOA (0.52) | BRD4CREBBPCYP2A6MAOAMAOB | |
| SCHEMBL13239543 | 0.79 | CYP1A2 (0.52) | BRD4CREBBPCYP1A2CYP2A6MAOA | |
| SCHEMBL2061251 | 0.79 | DRD1 (0.61) | CYP2A6MAOAMAOBDRD2DRD1 | |
| SCHEMBL13507876 | 0.79 | CYP1A2 (0.43) | BRD4CREBBPCYP1A2CYP2A6MAOA | |
| SCHEMBL21698587 | 0.76 | BRD4 (0.52) | BRD4CYP2A6MAOAMAOBDRD2 | |
| SCHEMBL5985141 | 0.76 | CYP11B2 (0.45) | HPGDCYP11B2ACHE | |
| SCHEMBL23957375 | 0.75 | P2RX7 (0.42) | CYP11B2 | |
| SCHEMBL21183690 | 0.75 | BRD4 (0.54) | BRD4CYP11B2 | |
| SCHEMBL21603396 | 0.75 | SMN1; SMN2 (0.42) | BRD4HPGDCYP11B2 | |
| SCHEMBL16942505 | 0.75 | KMT2A (0.41) | BRD4CREBBPNOTUMHPGDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051320-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240270699-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | LOMOND THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| CN-117843618-A | EP300/CBP regulator and preparation method and application thereof | 北京沐华生物科技有限责任公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11932635-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2024046504-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京沐华生物科技有限责任公司 | 2024-03-07 | — | — | WO | disclosed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2006107859-A2 | DIHYDROPYRIDINE COMPOUNDS FOR NEURODEGENERATIVE DISEASES AND DEMENTIA | EISAI CO., LTD. (JP) | 2006-10-12 | — | — | WO | disclosed |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | EISAI CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | EISAI CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| WO-2005087226-A1 | CADASIL TREATMENT WITH CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2005-09-22 | — | — | WO | disclosed |
| WO-2004034963-A2 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003092606-A2 | CHOLINESTERASE INHIBITORS TO PREVENT INJURIES CAUSED BY CHEMICALS | EISAI CO., LTD. (JP) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003024450-A1 | METHODS FOR TREATING PRION DISEASES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024456-A1 | METHODS FOR TREATING AND PREVENTING MIGRAINES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270699-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | IRAK3, IRAK1, IRAK2 | BRD4 224/4885CREBBP 1106/4885CYP1A2 4034/4885 |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | BRD4 1883/4885CREBBP 1369/4885CYP1A2 4670/4885 |
| US-11932635-B2 | CRBN ligands and uses thereof | CRBN, CRKL, ERBB3 | BRD4 1883/4885CREBBP 1369/4885CYP1A2 4670/4885 |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | ACHE, BPHL, GLA | BRD4 1086/4885CREBBP 1555/4885CYP1A2 3265/4885 |
| US-20250051320-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | BRD4 1883/4885CREBBP 1369/4885CYP1A2 4670/4885 |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | ACHE, CHAT, BCHE | BRD4 475/4885CREBBP 1114/4885CYP1A2 3185/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | BRD4 2991/4885CREBBP 3066/4885CYP1A2 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.